Secukinumab (AIN-457) for the treatment of Psoriasis

被引：10
|
作者：
Jaleel, Tarannum [1 ]
Elmets, Craig [1 ]
Weinkle, Allison [3 ]
Kassira, Sama [2 ]
Elewski, Boni [1 ]
机构：
[1] Univ Alabama Birmingham, Dept Dermatol, EFH 414,1530 3rd Ave S, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, Sch Med, Birmingham, AL 35294 USA
[3] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA
来源：
EXPERT REVIEW OF CLINICAL PHARMACOLOGY | 2016年 / 9卷 / 02期
关键词：
pharmacology; IL-17; Th; 17; AIN-457; psoriasis; secukinumab; SEVERE PLAQUE PSORIASIS; RANDOMIZED CONTROLLED-TRIAL; ANTI-INTERLEUKIN-17A MONOCLONAL-ANTIBODY; TO-SEVERE PSORIASIS; DOUBLE-BLIND; PHASE-III; OPEN-LABEL; MULTIPLE-SCLEROSIS; TH17; CELLS; INFLIXIMAB INDUCTION;
D O I：
10.1586/17512433.2016.1129894
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Secukinumab (also known as AIN-457) is a human monoclonal antibody targeting IL-17A, which has been recently FDA-approved for the treatment of moderate to severe psoriasis and psoriatic arthritis with coexistent moderate to severe plaque psoriasis based on clinical trials demonstrating excellent efficacy. This review will address the rationale for targeting the IL-23/Th17/IL-17 axis, the role of IL-17 and Th17 cells in psoriasis and other chronic inflammatory diseases, and will examine pre-clinical studies, pharmacologic properties, clinical efficacy, and the safety profile of secukinumab.
引用
收藏
页码：187 / 202
页数：16
相关论文
共 50 条
  • [21] Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study
    Galluzzo, Marco
    Talamonti, Marina
    Atzori, Laura
    Bardazzi, Federico
    Campanati, Anna
    Di Cesare, Antonella
    Diotallevi, Federico
    Flori, Maria Laura
    Mugheddu, Cristina
    Offidani, Annamaria
    Piaserico, Stefano
    Russo, Filomena
    Sacchelli, Lidia
    Bianchi, Luca
    Prignano, Francesca
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (04) : 547 - 554
  • [22] Secukinumab efficacy in the treatment of nail psoriasis: a case series
    Pistone, Giuseppe
    Gurreri, Rosario
    Tilotta, Giovanna
    Castelli, Elena
    Bongiorno, Maria Rita
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2018, 29 : 21 - 24
  • [23] In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis
    Galluzzo, Marco
    D'Adamio, Simone
    Silvaggio, Dionisio
    Lombardo, Paolo
    Bianchi, Luca
    Talamonti, Marina
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (02) : 173 - 182
  • [24] Atopic Dermatitis as a Paradoxical Effect of Secukinumab for the Treatment of Psoriasis
    Mendes Roncada, Eduardo, V
    Brambilla, Victoria Romanini
    Filitto, Beatriz Freitas
    Genta, Mariana Piraja
    Morgado de Abreu, Marilda Ap M.
    CASE REPORTS IN DERMATOLOGY, 2021, 13 (02): : 336 - 339
  • [25] Treatment of psoriasis with secukinumab Practical guidance
    Koerber, Andreas
    Augustin, Matthias
    Behrens, Frank
    Gerdes, Sascha
    von Kiedrowski, Ralph
    Schaekel, Knut
    Sticherling, Michael
    Wilsmann-Theis, Dagmar
    Wohlrab, Johannes
    Simon, Jan-Christoph
    HAUTARZT, 2021, 72 (11): : 984 - 991
  • [26] Anti-interleukin-17 treatment of psoriasis
    Jinna, Sphoorthi
    Strober, Bruce
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2016, 27 (04) : 311 - 315
  • [27] Apremilast Coadministered with Secukinumab for Safe and Effective Control of Psoriasis with Resultant Reduction of Maintenance Dose of the Biologic
    De, Abhishek
    Das, Sudip
    Dhoot, Dhiraj
    Sarda, Aarti
    INDIAN JOURNAL OF DERMATOLOGY, 2019, 64 (03) : 239 - 241
  • [28] Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis
    Hueber, Wolfgang
    Patel, Dhavalkumar D.
    Dryja, Thaddeus
    Wright, Andrew M.
    Koroleva, Irina
    Bruin, Gerard
    Antoni, Christian
    Draelos, Zoe
    Gold, Michael H.
    Durez, Patrick
    Tak, Paul P.
    Gomez-Reino, Juan J.
    Foster, C. Stephen
    Kim, Rosa Y.
    Samson, C. Michael
    Falk, Naomi S.
    Chu, David S.
    Callanan, David
    Quan Dong Nguyen
    Rose, Kristine
    Haider, Asifa
    Di Padova, Franco
    SCIENCE TRANSLATIONAL MEDICINE, 2010, 2 (52)
  • [29] Combination treatment with secukinumab and dimethyl fumarate in a patient with psoriasis and recent diagnosis of multiple sclerosis
    Di Tullio, Francesca
    Odorici, Giulia
    Lasagni, Claudia
    Capobianco, Marco
    Conti, Andrea
    Mandel, Victor Desmond
    DERMATOLOGIC THERAPY, 2020, 33 (06)
  • [30] Secukinumab in psoriasis patients with prior ustekinumab treatment: Results of a single-center experience
    Wang, Ting-Shun
    Chan, Chih-Chieh
    Chiu, Hsien-Yi
    Tsai, Tsen-Fang
    DERMATOLOGICA SINICA, 2017, 35 (01) : 25 - 29
12345